Association of DAPT duration with bleeding and ischemic outcomes after percutaneous coronary intervention with drug-coated balloons: a meta-analysis - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Impact of Dual Antiplatelet Therapy Duration on Bleeding and Ischemic Events Following Percutaneous Coronary Intervention with Drug-Coated Balloons: A Meta-Analysis

  • By

  • Giuseppe Panuccio

  • Nicole Carabetta

  • Martina Sportelli

  • Giuseppe Tartaglione

  • Kambis Mashayekhi

  • Emmanouil S. Brilakis

  • David M. Leistner

  • Sabato Sorrentino

  • Youssef Abdelwahed

  • Ulf Landmesser

  • Salvatore De Rosa

  • Daniele Torella

  • May 18, 2026

Share

  • 1

    Percutaneous coronary intervention with drug-coated balloons offers a stent-free alternative for treating coronary artery disease.

  • 2

    Current guidelines recommend at least 6 months of dual antiplatelet therapy after drug-eluting stent implantation.

  • 3

    The optimal duration of dual antiplatelet therapy after drug-coated balloon angioplasty remains poorly defined.

  • 4

    This meta-analysis aims to evaluate the association between dual antiplatelet therapy duration and clinical outcomes after drug-coated balloon procedures.

  • 5

    Subgroup analyses will explore the impact of different DAPT regimens and lesion settings on bleeding and ischemic events.

Original Source(s)

Association of DAPT duration with bleeding and ischemic outcomes after percutaneous coronary intervention with drug-coated balloons: a meta-analysis

  • by Giuseppe Panuccio, Nicole Carabetta, Martina Sportelli, Giuseppe Tartaglione, Kambis Mashayekhi, Emmanouil S. Brilakis, David M. Leistner, Sabato Sorrentino, Youssef Abdelwahed, Ulf Landmesser, Salvatore De Rosa, Daniele Torella

  • May 18, 2026

Related Content

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.

Invasive NSTEMI Strategy Shows No Benefit in Frail Patients

Frailty severity may identify older patients least likely to benefit—and potentially at higher risk—with invasive management.

Simplified radial artery haemostasis: using non-compressive dressings—the Radial Artery Puncture Haemostasis Evaluation trial: results of the RAPHE trial